ATE420887T1 - Cholesterol enthaltende verbindungen und deren verwendung als immunogen gegen borellia burgdorferi - Google Patents
Cholesterol enthaltende verbindungen und deren verwendung als immunogen gegen borellia burgdorferiInfo
- Publication number
- ATE420887T1 ATE420887T1 AT04758715T AT04758715T ATE420887T1 AT E420887 T1 ATE420887 T1 AT E420887T1 AT 04758715 T AT04758715 T AT 04758715T AT 04758715 T AT04758715 T AT 04758715T AT E420887 T1 ATE420887 T1 AT E420887T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds containing
- subject
- containing cholesterol
- immunogen against
- compounds
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 title abstract 2
- 235000012000 cholesterol Nutrition 0.000 title 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract 1
- 241000589969 Borreliella burgdorferi Species 0.000 abstract 1
- 229930186217 Glycolipid Natural products 0.000 abstract 1
- 208000016604 Lyme disease Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46018403P | 2003-04-02 | 2003-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE420887T1 true ATE420887T1 (de) | 2009-01-15 |
Family
ID=33159740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04758715T ATE420887T1 (de) | 2003-04-02 | 2004-04-02 | Cholesterol enthaltende verbindungen und deren verwendung als immunogen gegen borellia burgdorferi |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7666846B2 (de) |
| EP (2) | EP1613641B1 (de) |
| JP (1) | JP2006522808A (de) |
| CN (2) | CN100351265C (de) |
| AT (1) | ATE420887T1 (de) |
| AU (1) | AU2004228631B2 (de) |
| CA (1) | CA2521120A1 (de) |
| DE (1) | DE602004019063D1 (de) |
| ES (1) | ES2320998T3 (de) |
| RU (1) | RU2385323C2 (de) |
| WO (1) | WO2004089969A2 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080241069A1 (en) * | 2006-08-04 | 2008-10-02 | Yvonne Paterson | Methods and compositions for treating IgE-mediated diseases |
| US8286068B2 (en) * | 2008-04-25 | 2012-10-09 | Microsoft Corporation | Linking digital and paper documents |
| SI2569008T1 (sl) | 2010-05-14 | 2020-02-28 | Baxalta Incorporated | Himere OSPA in njihova uporaba v cepivih |
| US20230338495A1 (en) * | 2020-08-19 | 2023-10-26 | Vitruviae LLC | Vaccine Compositions and Antibodies For Lyme Disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK590288D0 (da) | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
| US3966918A (en) * | 1973-12-12 | 1976-06-29 | Nippon Shinyaku Co., Ltd. | Method of preparing aqueous solutions of sterol glycosides and their ester derivatives |
| GB1468473A (en) * | 1974-08-14 | 1977-03-30 | Nippon Shinyaku Co Ltd | Method for the preparation of steryl beta-d-glucoside palmitates |
| US4333926A (en) * | 1975-05-22 | 1982-06-08 | Nippon Shinyaku Co., Ltd. | Steryl-β-D-glucoside pharmaceutical compositions and use |
| JPS51139613A (en) * | 1975-05-24 | 1976-12-02 | Nippon Shinyaku Co Ltd | An absorbable non-crystalline sterol glycoside monopalmitate ester and a method for preparing its pharmaceutical |
| DE2523284B2 (de) * | 1975-05-26 | 1977-03-24 | Nippon Shiny aku Co., Ltd., Kyoto (Japan) | Haemostatische, gefaesstabilisierende und antischockmittel |
| US4254111A (en) * | 1978-07-05 | 1981-03-03 | Roecar Holdings (Netherlands Antilles) Nv | Sterolin products |
| US4189471A (en) * | 1978-07-11 | 1980-02-19 | Merck & Co., Inc. | Immunologic glycolipid adjuvants |
| US4229441A (en) * | 1978-12-01 | 1980-10-21 | Merck & Co., Inc. | Immunologic adjuvant |
| US4259324A (en) * | 1979-07-31 | 1981-03-31 | Merck & Co., Inc. | Immunologic adjuvant thio glycoside compounds and compositions |
| CA1195249A (en) * | 1983-03-21 | 1985-10-15 | Masanobu Kawamata | Liposome and manufacture method therefor |
| US5169637A (en) | 1983-03-24 | 1992-12-08 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| CA1237671A (en) | 1983-08-01 | 1988-06-07 | Michael W. Fountain | Enhancement of pharmaceutical activity |
| US4762915A (en) | 1985-01-18 | 1988-08-09 | Liposome Technology, Inc. | Protein-liposome conjugates |
| US4721617A (en) | 1986-08-14 | 1988-01-26 | Regents Of The University Of Minnesota | Vaccine against lyme disease |
| US5185154A (en) | 1989-02-02 | 1993-02-09 | Liposome Technology, Inc. | Method for instant preparation of a drug containing large unilamellar vesicles |
| GB9300125D0 (en) * | 1993-01-06 | 1993-03-03 | Scotia Holdings Plc | Compositions containing esters of unsaturated fatty acids |
| JP2779774B2 (ja) | 1994-08-31 | 1998-07-23 | 日清製油株式会社 | ステリルグリコシドの選択的アシル化方法 |
-
2004
- 2004-04-02 AT AT04758715T patent/ATE420887T1/de not_active IP Right Cessation
- 2004-04-02 WO PCT/US2004/010007 patent/WO2004089969A2/en not_active Ceased
- 2004-04-02 EP EP04758715A patent/EP1613641B1/de not_active Expired - Lifetime
- 2004-04-02 CN CNB2004800093119A patent/CN100351265C/zh not_active Expired - Fee Related
- 2004-04-02 JP JP2006509573A patent/JP2006522808A/ja active Pending
- 2004-04-02 ES ES04758715T patent/ES2320998T3/es not_active Expired - Lifetime
- 2004-04-02 CA CA002521120A patent/CA2521120A1/en not_active Abandoned
- 2004-04-02 US US10/550,907 patent/US7666846B2/en not_active Expired - Fee Related
- 2004-04-02 AU AU2004228631A patent/AU2004228631B2/en not_active Ceased
- 2004-04-02 EP EP08166066A patent/EP2030979A1/de not_active Withdrawn
- 2004-04-02 CN CNA2007101612908A patent/CN101195649A/zh active Pending
- 2004-04-02 DE DE602004019063T patent/DE602004019063D1/de not_active Expired - Lifetime
- 2004-04-02 RU RU2005133709/04A patent/RU2385323C2/ru not_active IP Right Cessation
-
2009
- 2009-07-29 US US12/511,337 patent/US20100062023A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004089969A3 (en) | 2004-12-16 |
| CN101195649A (zh) | 2008-06-11 |
| EP2030979A1 (de) | 2009-03-04 |
| WO2004089969A2 (en) | 2004-10-21 |
| CN100351265C (zh) | 2007-11-28 |
| RU2005133709A (ru) | 2006-05-10 |
| US20100062023A1 (en) | 2010-03-11 |
| US20060204515A1 (en) | 2006-09-14 |
| US7666846B2 (en) | 2010-02-23 |
| CA2521120A1 (en) | 2004-10-21 |
| EP1613641B1 (de) | 2009-01-14 |
| JP2006522808A (ja) | 2006-10-05 |
| CN1771256A (zh) | 2006-05-10 |
| AU2004228631B2 (en) | 2010-12-02 |
| AU2004228631A1 (en) | 2004-10-21 |
| EP1613641A2 (de) | 2006-01-11 |
| ES2320998T3 (es) | 2009-06-01 |
| DE602004019063D1 (de) | 2009-03-05 |
| RU2385323C2 (ru) | 2010-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124852T1 (el) | Φαρμακευτικες συνθεσεις 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλ) κυκλοπροπανοκαρβοξαμιδο)-3-μεθυλπυριδιν-2-υλ)βενζοϊκου οξεος και χορηγηση αυτων | |
| ATE269056T1 (de) | Hochwirksame dihydroergotaminhaltige arzneizusammensetzungen | |
| CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
| CO4950524A1 (es) | Inhibidores de acido nitrico sintasa | |
| ATE157257T1 (de) | Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen | |
| BRPI0415953A (pt) | formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação | |
| ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| ATE355065T1 (de) | Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika | |
| ATE330585T2 (de) | Behandlung von atemerkrankungen | |
| BR0110420A (pt) | Agonistas muscarìnicos | |
| ATE268179T1 (de) | Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung | |
| DE69231298D1 (de) | Substituierte Dibenzoxazepinverbindungen, pharmazeutische Zusammensetzungen und Anwendungsmethoden | |
| BRPI0117180B8 (pt) | composição farmacêutica em uma forma de unidade sólida de dosagem para a administração oral a um ser humano ou animal inferior | |
| RU2005105576A (ru) | Производные плевромутилина в качестве противомикроюных средств | |
| ATE156019T1 (de) | Lipophile zusammensetzungen von oligosaccharid- antibiotikasalzen | |
| ATE290858T1 (de) | N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin | |
| HRP20050103A2 (en) | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion | |
| DK1511496T3 (da) | Fremgangsmåde til behandling eller forebyggelse af immunmedierede sygdomme og farmaceutisk præparat til anvendelse heri | |
| ATE420887T1 (de) | Cholesterol enthaltende verbindungen und deren verwendung als immunogen gegen borellia burgdorferi | |
| Rasmussen et al. | Intraarticular glucocorticoid, morphine and bupivacaine reduces pain and convalescence after arthroscopic ankle surgery: a randomized study of 36 patients | |
| KR940013503A (ko) | 동맥경화증의 예방 또는 치료용 약제학적 조성물 | |
| DE69214586D1 (de) | Methanoanthracene als Dopaminantagonisten | |
| DK0991409T3 (da) | Farmaceutiske tiagabinindeholdende præparater med reguleret frigivelse | |
| BR0111464A (pt) | Composição farmacêutica na forma de dosagem unitária, e, método de tratamento de um paciente com nefropatia diabética | |
| DE69403110D1 (de) | Zyklische Angiopeptin Derivate, deren Herstellung und pharmazeutische Zusammensetzungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |